Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:AVDL OTCMKTS:CRLBF NASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$4.29-1.6%$4.02$3.21▼$7.18$1.04B0.64.19 million shs3.07 million shsAVDLAvadel Pharmaceuticals$11.03-2.0%$9.62$6.38▼$17.30$1.09B1.421.18 million shs760,479 shsCRLBFCresco Labs$0.68+8.0%$0.57$0.43▼$2.05$310.71M1.4632,931 shs1.16 million shsSANASana Biotechnology$4.95-3.5%$3.09$1.26▼$7.30$1.16B1.865.86 million shs5.32 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-1.61%-2.72%+18.18%-18.44%-23.67%AVDLAvadel Pharmaceuticals-1.96%+1.85%+16.84%+25.77%-32.33%CRLBFCresco Labs+8.03%+25.59%+36.61%-18.96%-58.32%SANASana Biotechnology-3.51%+6.91%+70.69%+179.66%-19.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.1121 of 5 stars3.51.00.04.42.72.50.6AVDLAvadel Pharmaceuticals1.9554 of 5 stars3.51.00.00.02.01.70.6CRLBFCresco Labs1.0217 of 5 stars0.04.00.00.02.30.01.3SANASana Biotechnology3.1815 of 5 stars3.53.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$10.89153.82% UpsideAVDLAvadel Pharmaceuticals 3.00Buy$18.3366.21% UpsideCRLBFCresco Labs 3.00BuyN/AN/ASANASana Biotechnology 3.00Buy$9.1785.19% UpsideCurrent Analyst Ratings BreakdownLatest CRLBF, ARDX, AVDL, and SANA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$22.007/3/2025SANASana BiotechnologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.006/24/2025SANASana BiotechnologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.006/18/2025ARDXArdelyxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.006/3/2025CRLBFCresco LabsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Moderate Buy5/8/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.00(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M3.08N/AN/A$0.73 per share5.88AVDLAvadel Pharmaceuticals$169.12M6.31N/AN/A$0.77 per share14.32CRLBFCresco Labs$724.34M0.46N/AN/A$0.79 per share0.87SANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A13.84N/A-14.86%-34.45%-13.81%8/4/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.27N/A183.83N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)CRLBFCresco Labs-$74.44M-$0.24N/AN/AN/A-11.86%-21.77%-6.00%8/7/2025 (Estimated)SANASana Biotechnology-$266.76M-$0.88N/AN/AN/AN/A-86.58%-44.49%8/6/2025 (Estimated)Latest CRLBF, ARDX, AVDL, and SANA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02N/AN/AN/AN/AN/A8/14/2025Q2 2025SANASana Biotechnology-$0.20N/AN/AN/AN/AN/A8/7/2025N/ACRLBFCresco Labs-$0.03N/AN/AN/A$162.00 millionN/A8/4/2025Q2 2025ARDXArdelyx-$0.12N/AN/AN/A$82.69 millionN/A5/30/2025Q1 2025CRLBFCresco Labs-$0.03-$0.04-$0.01-$0.04$164.37 million$165.76 million5/8/2025Q1 2025SANASana Biotechnology-$0.22-$0.20+$0.02-$0.21N/AN/A5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACRLBFCresco LabsN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.044.123.81AVDLAvadel PharmaceuticalsN/A2.732.33CRLBFCresco Labs1.632.751.98SANASana BiotechnologyN/A3.403.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%AVDLAvadel Pharmaceuticals69.19%CRLBFCresco Labs0.05%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%AVDLAvadel Pharmaceuticals5.20%CRLBFCresco LabsN/ASANASana Biotechnology30.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million227.77 millionOptionableAVDLAvadel Pharmaceuticals7096.74 million91.71 millionOptionableCRLBFCresco Labs2,900491.02 millionN/ANot OptionableSANASana Biotechnology380225.48 million157.61 millionOptionableCRLBF, ARDX, AVDL, and SANA HeadlinesRecent News About These CompaniesWorld-first obesity pill reprograms fat cells to burn calories with zero effortJuly 23 at 2:49 PM | newatlas.comNCiti Maintained a Buy Rating on Sana Biotechnology (SANA)July 23 at 2:49 PM | msn.comSana Biotechnology (NASDAQ:SANA) Stock Price Down 5.7% - Here's What HappenedJuly 21, 2025 | marketbeat.comSana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Rating of "Buy" from AnalystsJuly 17, 2025 | marketbeat.comSana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan StanleyJuly 11, 2025 | finance.yahoo.comSana Biotechnology (NASDAQ:SANA) Shares Gap Up - Here's WhyJuly 9, 2025 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Shares Up 14.1% - Still a Buy?July 8, 2025 | marketbeat.comSana Reports Promising Diabetes Cell Therapy Data at ADA MeetingJuly 4, 2025 | msn.comSana Biotechnology (NASDAQ:SANA) Coverage Initiated by Analysts at Morgan StanleyJuly 3, 2025 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Stock Price Up 7.6% - What's Next?July 2, 2025 | marketbeat.comSana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment ResultsJune 29, 2025 | insidermonkey.comSana Biotechnology’s SWOT analysis: promising cell therapy stock faces crowded market - Investing.comJune 26, 2025 | investing.comSana Biotechnology (SANA) Receives a Buy from Citizens JMPJune 26, 2025 | theglobeandmail.comBofA Remains Bullish on Sana Biotechnology (SANA)June 24, 2025 | insidermonkey.comSana Biotechnology stock soars after positive diabetes treatment resultsJune 23, 2025 | investing.comTwo Biotech Stocks Poised For Big Moves On MondayJune 23, 2025 | benzinga.comSana Biotechnology Shares Climb on Positive Diabetes Study ResultsJune 23, 2025 | marketwatch.comSana Biotechnology Reports Promising Six-Month Results from First-in-Human Study on Hypoimmune-Modified Pancreatic Islet Cell Transplant for Type 1 DiabetesJune 23, 2025 | quiverquant.comQSana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without ImmunosuppressionJune 23, 2025 | globenewswire.comSana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific SessionsJune 9, 2025 | globenewswire.comBiggest Stocks in NASDAQ Featuring Sana Biotechnology and KalkineJune 7, 2025 | kalkinemedia.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRLBF, ARDX, AVDL, and SANA Company DescriptionsArdelyx NASDAQ:ARDX$4.29 -0.07 (-1.61%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$4.28 -0.01 (-0.35%) As of 07/25/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Avadel Pharmaceuticals NASDAQ:AVDL$11.03 -0.22 (-1.96%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$11.07 +0.04 (+0.36%) As of 07/25/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Cresco Labs OTCMKTS:CRLBF$0.68 +0.05 (+8.03%) As of 07/25/2025 03:59 PM EasternCresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.Sana Biotechnology NASDAQ:SANA$4.95 -0.18 (-3.51%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$4.97 +0.02 (+0.40%) As of 07/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
